Lv11
40 积分 2024-03-13 加入
Cost–effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung
2小时前
待确认
Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer
3个月前
已完结
中国阿尔兹海默病痴呆诊疗指南
4个月前
已完结
Interstitial Lung Disease
5个月前
已完结
A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
7个月前
已完结
EE372 Modeling the Cost-Effectiveness in a Sub-Population: Tepotinib Versus Chemoimmunotherapy (C+IO) in Untreated Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METEX14) Skipping
9个月前
已完结
皖公网安备34019202002308
